Fresenius Medical Care
) and Apollo Medical Holdings, Inc. (ApolloMed, AMEH) revealed an
agreement under which ApolloMed subsidiary ApolloMed ACO is
joining hands with Fresenius Medical Care. Their purpose will be
to provide composite treatment for ApolloMed patients suffering
from end stage renal disease (ESRD).
Based in Glendale, California, ApolloMed is a doctor driven
composite health care provider. ApolloMed aims to provide top
class, cost effective care.
ApolloMed ACO is teaming with Fresenius Medical Care to
provide high quality medical attention required by ESRD patients.
Patients with ESRD require highly coordinated care as they are
likely to suffer from co-morbidities.
The two parties will share the management and cost savings
emanating from the agreement. This agreement has been tailored
after a 5-year demonstration project conducted by a subsidiary of
Fresenius Medical Care with Medicare enrollees on
Fresenius Medical Care is a large provider of products and
services for patients undergoing dialysis treatment. The
company's principal competitor in the U.S. is
DaVita HealthCare Partners Inc.
), which provides dialysis services for patients suffering from
chronic kidney failure or end stage renal disease. Fresenius
Medical Care also competes with
Baxter International Inc.
) in certain niches such as peritoneal dialysis products.
The company continues to register good operating results in
the North American as well as overseas markets. The integration
of acquisitions is also expected to be accretive to Fresenius
Medical Care's earnings in the near term. However, the contagion
of lingering economic problems in Europe remains a matter of
The stock carries a Zacks Rank #4 (Sell).
HeartWare International Inc.
) carries a Zacks Rank #2 (Buy) and is expected to do well.
BAXTER INTL (BAX): Free Stock Analysis Report
DAVITA INC (DVA): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis
HEARTWARE INTL (HTWR): Free Stock Analysis
To read this article on Zacks.com click here.